NCT04957290
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Radiation Therapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have at least one measurable lesion
Exclusions: Patients with tumor involvement of the central nervous system (e.g. brain or leptomeninges); Patients with oligometastatic disease (fewer than 5 metastatic lesions)
https://ClinicalTrials.gov/show/NCT04957290